Evidence map›Paper›PMID 30218193›Full record

ArticleLangenbeck's archives of surgery2018

Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.

Kenji Nakagawa, Takahiro Akahori, Satoshi Nishiwada, Minako Nagai, Kota Nakamura, Toshihiro Tanaka, Tetsuro Tamamoto, Chiho Ohbayashi, Masatoshi Hasegawa, Kimihiko Kichikawa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Observational
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kenji NakagawaDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Takahiro AkahoriDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Satoshi NishiwadaDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Minako NagaiDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Kota NakamuraDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Toshihiro TanakaDepartment of Radiology, Nara Medical University, Nara, Japan.
Tetsuro TamamotoDepartment of Radiation Oncology, Nara Medical University, Nara, Japan.
Chiho OhbayashiDepartment of Diagnostic Pathology, Nara Medical University, Nara, Japan.
Masatoshi HasegawaDepartment of Radiation Oncology, Nara Medical University, Nara, Japan.
Kimihiko KichikawaDepartment of Radiology, Nara Medical University, Nara, Japan.
Naoya IkedaDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
Masayuki ShoDepartment of Surgery, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. m-sho@naramed-u.ac.jp.ORCID http://orcid.org/0000-0002-6208-7661

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecent advances in multidisciplinary treatments are improving the postoperative prognosis of pancreatic ductal adenocarcinoma (PDAC). However, the prognosis even after potentially curative resection remains poor. The aim of this study was to identify the clinical and pathological features of actual 5-year survivors under current circumstances.

methodsA total of 128 patients who underwent pancreatectomy for PDAC at our institution between January 2006 and December 2011 were retrospectively analyzed.

resultsThe actual 5-year overall survival rate for all patients was 30.9%, with a median survival time of 33.1 months. Of 128 patients, 25 (19.5%) survived for 5 years after surgery without disease recurrence. A univariate analysis showed that the pretreatment serum CA19-9 value, tumor depth, lymph node metastasis, and UICC stage at resection were significant predictive factors for the actual long-term survival. A multivariate analysis showed that a pretreatment serum CA19-9 value ≥ 110 U/mL was a significant unfavorable prognostic indicator. In addition, all subjects in the 5-year survival group completed adjuvant chemotherapy. The recurrence rate in the liver was significantly lower and that in the lung significantly higher in the long-term survival group than in the short-term survival group.

conclusionsThe factors contributing to the long-term survival of PDAC were the pretreatment CA19-9 value and the completion of adjuvant chemotherapy. To achieve the actual long-term survival and cure after pancreatectomy for pancreatic cancer, further treatment strategies enhancing the completion rate of adjuvant chemotherapy are required.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCA-19-9 AntigenCarcinoma, Pancreatic DuctalCombined Modality TherapyFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPancreatectomyPancreatic NeoplasmsPrognosisBiomarkers, TumorCA-19-9 AntigenActual long-term survivalMultidisciplinary treatmentPancreatic cancerPrognostic factor

Identifiers

PMID30218193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.